 | |
| Company type | Public |
|---|---|
| KRX: 068270 | |
| Industry | Biopharmaceutical |
| Founded | 2002 |
| Founder | Seo Jung-jin |
| Headquarters | Yeonsu-gu, Incheon, South Korea |
Area served | Worldwide |
Key people | Seo Jung-jin, Chairman Kee Woo-sung, CEO |
| Products | Remsima™, Truxima™, Herzuma™, Biosimilar Drug |
| Revenue |  ₩828,917 million (2017)[1] |
| ₩517,385 million (2017)[1] | |
| ₩403,181 million (2017)[1] | |
| Total assets | ₩3,255,319 million (2017)[1] |
| Total equity | ₩2,522,076 million (2017)[1] |
| Owner | Celltrion Holdings Co., Ltd. (23.03%) Ion Investments B.V. (9.54%) National Pension Service (6.07%) |
| Subsidiaries | Celltrion Entertainment |
| Website | www |
Celltrion, Inc. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.[2] Celltrion's founder, Seo Jung-jin, is the richest person in South Korea.[3] Seo Jung-jin, its founder was awarded the 2021 EY World Entrepreneur Of The Year.[4]
- ^ a b c d e "Financial Information Celltrion Co., Ltd". Celltrion.
- ^ "Company Overview of Celltrion Healthcare Co., Ltd". Bloomberg.
- ^ Kang, John. "Korea's New No. 1: Celltrion Cofounder Becomes First Self-Made Billionaire To Claim Top Spot". Forbes. Retrieved 2021-08-06.
- ^ "Jung Jin SEO - EY World Entrepreneur Of The Year™ 2024 Judges". www.ey.com. Retrieved 2024-11-08.